Isoniazid-induced liver injury and immune response in mice

References

• Black, M., Mitchell, J. R., Zimmerman, H. J., et al. 1975. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69:289–302
   PubMed Web of Science ®Google Scholar
• Blair, I. A., Mansilla Tinoco, R., Brodie, M. J., et al. 1985. Plasma hydrazine concentrations in man after isoniazid and hydralazine administration. Human Toxicol. 4:195–202
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). 2010. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004–2008. MMWR 59:224–229
   PubMedGoogle Scholar
• Crispe, I. N., Dao, T., Klugewitz, K., et al. 2000. The liver as a site of T-cell apoptosis: Graveyard, or killing field? Immunol. Rev. 174:47–62
   Google Scholar
• de Boer, L. C., Steerenberg, P. A., van der Meijden, P. M., et al. 1992. Impaired immune response by isoniazid treatment during intra-vesical BCG administration in the guinea pig. J. Urol. 148:1577–1582
   PubMed Web of Science ®Google Scholar
• Fukino, K., Sasaki, Y., Hirai, S., et al. 2008. Effects of N-acetyltransferase 2 (NAT2), CYP2E1, and glutathione-S-transferase (GST) genotypes on serum concentrations of isoniazid and metabolites in tuberculosis patients. Toxicol. Sci. 33:187–195
   Web of Science ®Google Scholar
• Gent, W. L., Seifart, H. I., Parkin, D. P., et al. 1992. Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients. Eur. J. Clin. Pharmacol. 43:131–136
   PubMed Web of Science ®Google Scholar
• Huang, Y. S., Chern, H. D., Su, W. J., et al. 2002. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for anti-tuberculosis drug-induced hepatitis. Hepatology 35:883–889
   PubMed Web of Science ®Google Scholar
• Jones, S. A., Moore, L. B., Shenk, J. L., et al. 2000. The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14:27–39
   PubMed Web of Science ®Google Scholar
• Laskin, D. L. 2009. Macrophages and inflammatory mediators in chemical toxicity: A battle of forces. Chem. Res. Toxicol. 22:1376–1385
   PubMed Web of Science ®Google Scholar
• Lehmann, J. M., McKee, D. D., Watson, M. A., et al. 1998. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102:1016–1023
   PubMed Web of Science ®Google Scholar
• Maddrey, W. C., and Boitnott, J. K. 1973. Isoniazid hepatitis. Ann. Int. Med. 79:1–12
   PubMed Web of Science ®Google Scholar
• Metushi, I. G., Cai, P., Zhu, X., et al. 2011. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin. Pharmacol. Ther. 89:911–914
   PubMed Web of Science ®Google Scholar
• Metushi, I. G., Nakagawa, T., and Uetrecht, J. 2012. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: Humans are more like mice than rats. Chem. Res. Toxicol. 25:2567–2576
   PubMed Web of Science ®Google Scholar
• Metushi, I. G., Sanders, C., Lee, W. M., and Uetrecht, J. 2013. Detection of anti-isoniazid and anti-cyp antibodies in patients with isoniazid-induced liver failure. Hepatology (Epub ahead of print)
   Google Scholar
• Mitchell, J. R., Zimmerman, H. J., Ishak, K. G., et al 1976. Isoniazid liver injury: Clinical spectrum, pathology, and probable pathogenesis. Ann. Int. Med. 84:181–192
   PubMed Web of Science ®Google Scholar
• Naisbitt, D. J., Gordon, S. F., Pirmohamed, M., and Park, B. K. 2000. Immunological principles of adverse drug reactions: The initiation and propagation of immune responses elicited by drug treatment. Drug Safety 23:483–507
   PubMed Web of Science ®Google Scholar
• Noda, A., Hsu, K. Y., Noda, H., et al. 1983. Is isoniazid-hepatotoxicity induced by the metabolite, hydrazine? J. UOEH 5:183–190
   PubMedGoogle Scholar
• Onizuka, S., Tawara, I., Shimizu, J., et al. 1999. Tumor rejection by in vivo administration of anti-CD25 (IL-2Rα) monoclonal antibody. Cancer Res. 59:3128–3133
   PubMed Web of Science ®Google Scholar
• Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:252–264
   PubMed Web of Science ®Google Scholar
• Quintana, F. J., Basso, A. S., Iglesias, A. H., et al. 2008. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature 453:65–71
   PubMed Web of Science ®Google Scholar
• Salazar-Paramo, M., Rubin, R. L., and Garcia de la Torre, I. 1992. Systemic lupus erythematosus induced by isoniazid. Ann. Rheum. Dis. 51:1085–1087
   PubMed Web of Science ®Google Scholar
• Sarich, T. C., Youseffi, M., Zhou, T., et al. 1996. Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Arch. Toxicol. 70:835–840
   PubMed Web of Science ®Google Scholar
• Sharma, S. K., Balamurugan, A., Saha, P. K., et al. 2002. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti-tuber-culosis treatment. Am. J. Resp. Crit. Care Med. 166:916–919
   PubMed Web of Science ®Google Scholar
• Soyer, O. U., Akdis, M., Ring, J., et al. 2013. Mechanisms of peripheral tolerance to allergens. Allergy 68:161–170
   PubMed Web of Science ®Google Scholar
• Stassar, M. J., Vegt, P. D., Steerenberg, P. A., et al. 1994. Effects of isoniazid (INH) on the BCG-induced local immune response after intra-vesical BCG therapy for superficial bladder cancer. Urol. Res. 22:177–184
   PubMedGoogle Scholar
• Tiegs, G., and Lohse, A. W. 2010. Immune tolerance: What is unique about the liver? J. Autoimmun. 34:1–6
   Web of Science ®Google Scholar
• Venuprasad, K. 2010. Cbl-b and itch: Key regulators of peripheral T-cell tolerance. Cancer Res. 70:3009–3012
   PubMed Web of Science ®Google Scholar
• Warrington, R. J., McPhillips-Feener, S., and Rutherford, W. J. 1982. The predictive value of the lymphocyte transformation test in isoniazid-associated hepatitis. Clin. Allergy 12:217–222
   PubMedGoogle Scholar
• Warrington, R. J., Tse, K. S., Gorski, B. A., et al. 1978. Evaluation of isoniazid-associated hepatitis by immunological tests. Clin. Exp. Immunol. 32:97–104
   PubMed Web of Science ®Google Scholar
• Whitehouse, L. W., Tryphonas, L., Paul, C. J., et al. 1983. Isoniazid-induced hepatic steatosis in rabbits: An explanation for susceptibility and its antagonism by pyridoxine hydrochloride. Can. J. Physiol. Pharmacol. 61:478–487
   PubMed Web of Science ®Google Scholar
• Zimmerman, H. J. (Ed.). 1999. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia, PA: Lippincott Williams & Wilkins
   Google Scholar